Management of suspected or confirmed exposure to human T-cell lymphotropic virus type I
Centers for Disease Control and Prevention (CDC) 2016Hewagama 2014
Data on the efficacy of postexposure prophylaxis (PEP) against human T-cell lymphotropic virus type I (HTLV-I) are inconclusive. Seek expert advice for patients with possible exposure to human T-cell lymphotropic virus type I. For higher-risk exposures (eg percutaneous injury with a hollow blood-containing needle) in adults, consider using:
lamivudine+zidovudine 150+300 mg orally, 12-hourly for 4 weeks. For dosage adjustment in adults with kidney impairment, see lamivudine+zidovudine dosage adjustment. lamivudine + zidovudine lamivudine+zidovudine (Combivir) lamivudine+zidovudine (Combivir)